Carlos Portera-Cailliau, MD, on EPAC2 as potential therapeutic target in Fragile X syndrome
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
A preclinical study has identified a potential therapeutic target for fragile x syndrome. The target in question is epac2, which may have implications for treating the condition. Research on this potential target has been discussed by carlos portera-cailliau, md.